CN107708733B - 抗分拣蛋白抗体和其使用方法 - Google Patents

抗分拣蛋白抗体和其使用方法 Download PDF

Info

Publication number
CN107708733B
CN107708733B CN201680032832.9A CN201680032832A CN107708733B CN 107708733 B CN107708733 B CN 107708733B CN 201680032832 A CN201680032832 A CN 201680032832A CN 107708733 B CN107708733 B CN 107708733B
Authority
CN
China
Prior art keywords
sortilin
antibody
amino acid
seq
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680032832.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN107708733A (zh
Inventor
A·罗森塔尔
T·施瓦贝
M·科内尔拉斯
R·佩哈尔
A·库珀
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ai Lituo
Original Assignee
Ai Lituo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ai Lituo filed Critical Ai Lituo
Publication of CN107708733A publication Critical patent/CN107708733A/zh
Application granted granted Critical
Publication of CN107708733B publication Critical patent/CN107708733B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
CN201680032832.9A 2015-04-07 2016-04-07 抗分拣蛋白抗体和其使用方法 Active CN107708733B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562144270P 2015-04-07 2015-04-07
US62/144,270 2015-04-07
PCT/US2016/026519 WO2016164637A1 (en) 2015-04-07 2016-04-07 Anti-sortilin antibodies and methods of use thereof

Publications (2)

Publication Number Publication Date
CN107708733A CN107708733A (zh) 2018-02-16
CN107708733B true CN107708733B (zh) 2022-11-15

Family

ID=57072459

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680032832.9A Active CN107708733B (zh) 2015-04-07 2016-04-07 抗分拣蛋白抗体和其使用方法

Country Status (22)

Country Link
US (10) US10087255B2 (enExample)
EP (2) EP3991748A3 (enExample)
JP (4) JP6999421B2 (enExample)
CN (1) CN107708733B (enExample)
AU (1) AU2016245807B2 (enExample)
CA (1) CA2981851A1 (enExample)
CY (1) CY1124771T1 (enExample)
DK (1) DK3280441T3 (enExample)
EA (1) EA201792221A1 (enExample)
ES (1) ES2899227T3 (enExample)
HR (1) HRP20211980T1 (enExample)
HU (1) HUE057432T2 (enExample)
IL (1) IL254887B2 (enExample)
LT (1) LT3280441T (enExample)
MX (1) MX393951B (enExample)
PL (1) PL3280441T3 (enExample)
PT (1) PT3280441T (enExample)
RS (1) RS62546B1 (enExample)
SG (2) SG11201708220RA (enExample)
SI (1) SI3280441T1 (enExample)
SM (1) SMT202200065T1 (enExample)
WO (1) WO2016164637A1 (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10053513B2 (en) * 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
JP6999421B2 (ja) 2015-04-07 2022-02-04 アレクトル エルエルシー 抗ソルチリン抗体及びその使用方法
US10849992B1 (en) 2015-04-07 2020-12-01 Alector Llc Methods of screening for sortilin binding antagonists
GB201512215D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
CA3071494C (en) 2015-11-24 2021-12-14 Transfert Plus, S.E.C. Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy
MA43660A (fr) 2016-01-22 2018-11-28 Adimab Llc Anticorps anti-facteur xi de coagulation
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
TWI752964B (zh) 2016-06-14 2022-01-21 美商默沙東藥廠 抗凝血因子ｘｉ抗體
WO2018148447A1 (en) * 2017-02-08 2018-08-16 Adimab, Llc Antibody heavy chain variable domains targeting the nkg2d receptor
EP3579848B1 (en) 2017-02-08 2024-10-30 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
JP7685821B2 (ja) 2017-02-20 2025-05-30 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｈｅｒ２、ＮＫＧ２ＤおよびＣＤ１６に結合するタンパク質
US11932694B2 (en) 2017-04-19 2024-03-19 Bluefin Biomedicine, Inc. Anti-VTCN1 antibodies and antibody drug conjugates
US20200157151A1 (en) * 2017-05-24 2020-05-21 Transfert Plus, S.E.C. Peptide compounds, conjugate compounds and uses thereof for treating inflammatory diseases
TWI790120B (zh) 2017-06-02 2023-01-11 美商輝瑞大藥廠 對flt3具特異性之抗體及其用途
US10894833B2 (en) * 2017-07-20 2021-01-19 H. Lundbeck A/S Agents, uses and methods for treatment
US11833187B2 (en) 2017-10-23 2023-12-05 The Brigham And Women's Hospital, Inc. Materials and methods for extracellular vessicle-associated diseases
CA3079215A1 (en) 2017-10-24 2019-05-02 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cd117+ cells
WO2019084067A1 (en) * 2017-10-24 2019-05-02 Magenta Therapeutics, Inc. ANTI-CD117 ANTIBODIES AND METHODS OF USE
WO2019084064A2 (en) 2017-10-24 2019-05-02 Magenta Therapeutics, Inc. COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS
KR20200118029A (ko) 2018-01-04 2020-10-14 아이코닉 테라퓨틱스, 인코포레이티드 항-조직 인자 항체, 항체-약물 결합체, 및 관련 방법
MX2020008336A (es) 2018-02-08 2020-09-21 Dragonfly Therapeutics Inc Dominios variables de anticuerpos que se dirigen al receptor nkg2d.
BR112020015994A2 (pt) 2018-02-08 2020-12-15 Dragonfly Therapeutics, Inc. Terapia de combinação do câncer que envolve proteínas de ligação multiespecíficas que ativam células natural killer
PE20211224A1 (es) * 2018-02-20 2021-07-06 Dragonfly Therapeutics Inc Dominios variables de anticuerpo que se dirigen a cd33 y sus usos
JP7353576B2 (ja) 2018-02-20 2023-10-02 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｃｄ３３、ｎｋｇ２ｄ、及びｃｄ１６に結合する多重特異性結合タンパク質、ならびにその使用方法
CN112867496A (zh) * 2018-03-27 2021-05-28 史密斯治疗公司 用于治疗神经退行性疾病的基于car-treg的疗法
AU2019288212A1 (en) * 2018-06-18 2020-12-03 Denali Therapeutics Inc. Fusion proteins comprising progranulin
PE20210186A1 (es) 2018-07-13 2021-02-02 Alector Llc Anticuerpos anti-sortilina y metodos para su uso
EA202190468A1 (ru) 2018-08-08 2021-07-06 Драгонфлай Терапьютикс, Инк. Мультиспецифические связывающие белки, которые связывают bcma, nkg2d и cd16, и способы их применения
SG11202101298XA (en) 2018-08-08 2021-03-30 Dragonfly Therapeutics Inc Proteins binding nkg2d, cd16 and a tumor-associated antigen
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
TW202028237A (zh) * 2018-09-27 2020-08-01 美商西建公司 SIRPα結合蛋白及其使用方法
US11591390B2 (en) 2018-09-27 2023-02-28 Celgene Corporation SIRP-α binding proteins and methods of use thereof
CA3140023A1 (en) * 2019-06-11 2020-12-17 Alector Llc Anti-sortilin antibodies for use in therapy
CA3142632A1 (en) * 2019-07-03 2021-01-07 Crystal Bioscience Inc. Anti-cd38 antibody and methods of use thereof
CN114222752B (zh) * 2019-07-03 2025-11-14 埃克塞里艾克西斯公司 抗组织因子抗体-药物缀合物及相关方法
WO2021116290A1 (en) * 2019-12-10 2021-06-17 Aarhus Universitet Compounds for treatment of eye diseases
US20230212266A1 (en) * 2020-04-27 2023-07-06 Fred Hutchinson Cancer Center Neutralizing monoclonal antibodies against covid19
AR122018A1 (es) 2020-05-06 2022-08-03 Dragonfly Therapeutics Inc Proteínas que se unen a nkg2d, cd16 y clec12a
CN116249717A (zh) 2020-06-24 2023-06-09 普罗塞纳生物科学有限公司 识别分拣蛋白的抗体
EP3981394A1 (en) * 2020-10-07 2022-04-13 Insusense ApS A sortilin antagonist for use in the prevention or treatment of hearing loss.
EP4229419A2 (en) 2020-10-14 2023-08-23 Denali Therapeutics Inc. Methods for treating and monitoring frontotemporal dementia
KR20230117169A (ko) 2020-12-02 2023-08-07 알렉터 엘엘씨 항-소르틸린 항체의 사용 방법
WO2022120423A1 (en) * 2020-12-08 2022-06-16 James Cook University Peptides and uses thereof
CN117222663A (zh) 2021-03-03 2023-12-12 蜻蜓疗法股份有限公司 使用结合nkg2d、cd16和肿瘤相关抗原的多特异性结合蛋白治疗癌症的方法
AU2022277698A1 (en) * 2021-05-19 2023-12-14 Biohaven Therapeutics Ltd. Antibody drug conjugates using mates technology for delivering cytotoxic agents
US20250019427A1 (en) * 2021-08-10 2025-01-16 Byomass Inc. Anti-gdf15 antibodies, compositions and uses thereof
SE545408C2 (en) 2021-12-02 2023-09-05 Sortina Pharma Ab Sortilin inhibitors
CA3242070A1 (en) * 2021-12-23 2023-06-29 Andriani IOANNOU Antibodies recognizing sortilin
CN119630807A (zh) * 2022-05-03 2025-03-14 爱莫布瑞斯疗法公司 重组抗体产生方法和相关细胞系统
CA3259108A1 (en) * 2022-06-16 2023-12-21 Cephalon Llc Attenuated Anti-PD1-IL2 Immunoconjugates and Their Uses
CA3252861A1 (en) 2022-06-23 2023-12-28 Draupnir Bio Aps Bifunctional molecules that selectively induce the degradation of extracellular targets in lysosomes
WO2024245719A1 (en) 2023-05-26 2024-12-05 Charité - Universitätsmedizin Berlin Sortilin inhibitors for treatment of patients with functional neuroendocrine tumors
WO2025166073A1 (en) * 2024-01-31 2025-08-07 Alector Llc Compositions comprising anti-sortilin antibodies and uses thereof

Family Cites Families (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
ES2058199T3 (es) 1987-09-23 1994-11-01 Bristol Myers Squibb Co Heteroconjugados de anticuerpos para la eliminacion de celulas infectadas por el vih.
EP0435911B1 (en) 1988-09-23 1996-03-13 Cetus Oncology Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69029036T2 (de) 1989-06-29 1997-05-22 Medarex Inc Bispezifische reagenzien für die aids-therapie
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
EP0547065B1 (en) 1990-06-29 2001-08-29 Large Scale Biology Corporation Melanin production by transformed microorganisms
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル，インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
JPH06507398A (ja) 1991-05-14 1994-08-25 リプリジェン　コーポレーション Ｈｉｖ感染治療のための異種複合抗体
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
JP3951062B2 (ja) 1991-09-19 2007-08-01 ジェネンテック・インコーポレーテッド 少なくとも遊離のチオールとして存在するシステインを有する抗体フラグメントの大腸菌での発現、２官能性Ｆ（ａｂ’）２抗体の産生のための使用
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
EP1136556B1 (en) 1991-11-25 2005-06-08 Enzon, Inc. Method of producing multivalent antigen-binding proteins
WO1993011794A1 (en) 1991-12-13 1993-06-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
EP1997894B1 (en) 1992-02-06 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Biosynthetic binding protein for cancer marker
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
CA2140280A1 (en) 1992-08-17 1994-03-03 Avi J. Ashkenazi Bispecific immunoadhesins
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
JP2002514895A (ja) 1995-09-28 2002-05-21 アレクション、ファーマスーティカルズ、インコーポレーテッド ブタ細胞相互作用タンパク質
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
ES2301183T3 (es) 1996-12-03 2008-06-16 Amgen Fremont Inc. Anticuerpo completamente humano que se une al receptor del egfr.
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
ATE531812T1 (de) 1997-12-05 2011-11-15 Scripps Research Inst Humanisierung von nager-antikörpern
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
EP1222292B1 (en) 1999-10-04 2005-08-31 Medicago Inc. Method for regulating transcription of foreign genes in the presence of nitrogen
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
PT2857516T (pt) 2000-04-11 2017-08-28 Genentech Inc Anticorpos multivalentes e utilizações dos mesmos
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
KR100857943B1 (ko) 2000-11-30 2008-09-09 메다렉스, 인코포레이티드 인간 항체의 제조를 위한 형질전환 트랜스염색체 설치류
NZ532526A (en) 2001-10-25 2007-01-26 Genentech Inc Compositions comprising a glycoprotein having a Fc region
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
JPWO2003085118A1 (ja) 2002-04-09 2005-08-11 協和醗酵工業株式会社 抗体組成物の製造方法
WO2003084569A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Drug containing antibody composition
JP4628679B2 (ja) 2002-04-09 2011-02-09 協和発酵キリン株式会社 Ｇｄｐ−フコースの輸送に関与する蛋白質の活性が低下または欠失した細胞
MXPA04009924A (es) 2002-04-09 2005-07-01 Kyowa Hakko Kogyo Kk Celulas de genoma modificado.
WO2004042072A2 (en) 2002-11-01 2004-05-21 The Regents Of The University Of Colorado, A Body Corporate Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry
EP1891966B1 (en) 2002-12-20 2012-02-15 H. Lundbeck A/S Modulation of activity of neurotrophins; screening method
EP1682170A2 (en) 2003-11-07 2006-07-26 Lay Line Genomics SpA Compositions able to prevent neurodegenerative processes and methods of assaying the same
WO2005097832A2 (en) 2004-03-31 2005-10-20 Genentech, Inc. Humanized anti-tgf-beta antibodies
US20080181888A1 (en) 2004-12-31 2008-07-31 Ambrose Christine M Polypeptides That Bind Br3 and Uses Thereof
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
WO2006138343A2 (en) 2005-06-14 2006-12-28 Raptor Pharmaceutical Inc. Compositions comprising receptor - associated protein (rap) variants specific for lrp2 and uses thereof
KR101888321B1 (ko) * 2005-07-01 2018-08-13 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
EP1945240B1 (en) 2005-09-16 2016-12-28 Raptor Pharmaceutical Inc Compositions comprising receptor-associated protein (rap) variants specific for cr-containing proteins and uses thereof
FR2896881B1 (fr) 2006-01-31 2008-04-18 Biomerieux Sa Procede de dosage du prongf pour le diagnostic in vitro du cancer du sein et utilisation du prongf en therapie
WO2007106585A1 (en) 2006-03-15 2007-09-20 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
EP2016101A2 (en) 2006-05-09 2009-01-21 Genentech, Inc. Binding polypeptides with optimized scaffolds
PL2059533T3 (pl) 2006-08-30 2013-04-30 Genentech Inc Przeciwciała wieloswoiste
WO2008036682A2 (en) 2006-09-18 2008-03-27 Raptor Pharmaceutical Inc. Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
WO2008052016A2 (en) 2006-10-23 2008-05-02 Columbia University The sortilin-related receptor sorl1 is functionally and genetically associated with alzheimer's disease
WO2008076262A2 (en) * 2006-12-15 2008-06-26 Merck & Co., Inc. Receptor for amyloid beta and uses thereof
DK3225251T3 (da) 2006-12-21 2020-03-16 H Lundbeck As Modulering af pro-neurotrofinaktivitet
UY30776A1 (es) 2006-12-21 2008-07-03 Medarex Inc Anticuerpos cd44
WO2008086452A2 (en) 2007-01-10 2008-07-17 Columbia University Treatment and prevention of alzheimer's disease
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
CN101855242B (zh) 2007-09-14 2014-07-30 阿迪马布有限责任公司 合理设计的合成抗体文库及其用途
AU2009204501B2 (en) 2008-01-07 2015-02-12 Amgen Inc. Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
US8377701B2 (en) * 2008-04-27 2013-02-19 H. Lundbeck A/S Specific ligands to sortilin
US20160359907A1 (en) 2015-06-02 2016-12-08 Vmware, Inc. Automatically auditing virtual machines for security hardening compliance
US9084745B2 (en) 2008-05-22 2015-07-21 H. Lundback A/S Modulation of the Vps10p-domain for the treatment of cardiovascular disease
EP2732823B1 (en) 2008-06-25 2019-08-07 H. Lundbeck A/S Modulation of the TrpV : Vps10p-domain receptor system for the treatment of pain
PL3009449T3 (pl) * 2008-07-16 2018-09-28 Institute For Research In Biomedicine Przeciwciała neutralizujące ludzkie cytomegalowirusy i ich zastosowanie
US20120039865A1 (en) * 2008-08-19 2012-02-16 Yale University Identification of sortilin as a neuronal receptor for the frontotemporal dementia protein, progranulin
WO2010028333A2 (en) 2008-09-08 2010-03-11 Mayo Foundation For Medical Education And Research Methods and devices for ligating tubular structures
EP2379593A2 (en) 2008-12-19 2011-10-26 H. Lundbeck A/S Modulation of the vps 10-domain receptor family for the treatment of mental and behavioural disorders
FR2945538B1 (fr) 2009-05-12 2014-12-26 Sanofi Aventis Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
EP2483406A2 (en) 2009-09-30 2012-08-08 President and Fellows of Harvard College Methods for modulation of autophagy through the modulation of autophagy-inhibiting gene products
US20130115222A1 (en) 2010-06-15 2013-05-09 Cornell University Methods of limiting microvascular damage following acute myocardial ischemia
EP3336225B1 (en) 2010-07-16 2020-02-19 Adimab, LLC Antibody libraries
US20130336988A1 (en) 2010-11-17 2013-12-19 New York University Methods for treating early stage or mild neurological disorders
CN103649123B (zh) 2011-06-13 2017-05-24 Csl有限公司 抗g‑csfr抗体及其用途
WO2014071131A1 (en) 2012-11-02 2014-05-08 The Brigham And Women's Hospital, Inc. Sortilin 1 is a novel inducer of vascular calcification
US10156574B2 (en) 2013-04-29 2018-12-18 Adimab, Llc Polyspecificity reagents, methods for their preparation and use
SI3019240T1 (sl) 2013-07-09 2024-07-31 Annexon, Inc. Protitelesa proti komplementnemu faktorju C1q in njihova uporaba
WO2015119989A1 (en) 2014-02-04 2015-08-13 New York University Progranulin (pgrn) and its derivatives for diagnosis and treatment of lysosomal storage diseases
HK1232289A1 (zh) 2014-02-12 2018-01-05 H. Lundbeck A/S 分拣蛋白作为针对情感/心境障碍的生物标记的用途
WO2015144860A1 (en) * 2014-03-26 2015-10-01 Goran Landberg Agents inhibiting granulin for treatment of cancer
US10603364B2 (en) 2014-08-11 2020-03-31 Shire Human Genetic Therapies, Inc. Lysosomal targeting and uses thereof
US10849992B1 (en) * 2015-04-07 2020-12-01 Alector Llc Methods of screening for sortilin binding antagonists
JP6999421B2 (ja) 2015-04-07 2022-02-04 アレクトル エルエルシー 抗ソルチリン抗体及びその使用方法
US20160331746A1 (en) 2015-05-12 2016-11-17 University Of South Florida Sortilin-Binding Small Molecules for Increasing Glucose Uptake
GB201512215D0 (en) * 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
WO2017024137A1 (en) 2015-08-04 2017-02-09 New York University Progranulin (pgrn) fragments and derivatives for treatment or alleviation of lysosomal storage diseases
US10085969B1 (en) 2016-02-12 2018-10-02 University Of South Florida Sortilin binding compounds, formulations, and uses thereof
US10894833B2 (en) 2017-07-20 2021-01-19 H. Lundbeck A/S Agents, uses and methods for treatment
US11833187B2 (en) 2017-10-23 2023-12-05 The Brigham And Women's Hospital, Inc. Materials and methods for extracellular vessicle-associated diseases
AU2019288212A1 (en) 2018-06-18 2020-12-03 Denali Therapeutics Inc. Fusion proteins comprising progranulin
PE20210186A1 (es) 2018-07-13 2021-02-02 Alector Llc Anticuerpos anti-sortilina y metodos para su uso
US20220000971A1 (en) 2018-08-24 2022-01-06 Transfert Plus, S.E.C. Methods and compounds for targeting sortilin receptors and inhibiting vasculogenic mimicry
WO2020051624A1 (en) 2018-09-11 2020-03-19 Grophin Pty Ltd Methods and compositions for improving recovery from a brain injury
EP3666281A1 (en) 2018-12-14 2020-06-17 Insusense ApS Compositions comprising sortilin-1
EP3942049A4 (en) 2019-03-20 2023-10-18 President And Fellows Of Harvard College ANTISENSE OLIGONUCLEOTIDE BASED PROGRANULIN AUGMENTATION THERAPY FOR NEURODEGENERATIVE DISEASES
CA3140023A1 (en) 2019-06-11 2020-12-17 Alector Llc Anti-sortilin antibodies for use in therapy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Targeted manipulation of the sortilin-progranulin axis rescues progranulin haploinsufficiency;Lee, Wing C.; Almeida, Sandra; Prudencio, Mercedes; 等.;《HUMAN MOLECULAR GENETICS》;20140315;第23卷(第6期);全文 *
The neurotrophic properties of progranulin depend on the granulin E domain but do not require sortilin binding;Louis De Muynck, Sarah Herdewyn, Sander Beel等;《Neurobiology of Aging》;20130524;第34卷(第11期);全文 *

Also Published As

Publication number Publication date
US20200223928A1 (en) 2020-07-16
EP3280441B1 (en) 2021-09-29
US11208488B2 (en) 2021-12-28
US20220251219A1 (en) 2022-08-11
US11186645B2 (en) 2021-11-30
US20180265586A1 (en) 2018-09-20
US11339223B2 (en) 2022-05-24
CN107708733A (zh) 2018-02-16
JP2018517401A (ja) 2018-07-05
JP2023029891A (ja) 2023-03-07
AU2016245807B2 (en) 2022-05-19
HUE057432T2 (hu) 2022-05-28
US20250092144A1 (en) 2025-03-20
JP6999421B2 (ja) 2022-02-04
AU2016245807A1 (en) 2017-11-02
PL3280441T3 (pl) 2022-02-21
US20190085084A1 (en) 2019-03-21
IL254887B2 (en) 2023-11-01
EP3280441A1 (en) 2018-02-14
CA2981851A1 (en) 2016-10-13
US20190127475A1 (en) 2019-05-02
CY1124771T1 (el) 2022-11-25
IL254887A0 (en) 2017-12-31
US10087255B2 (en) 2018-10-02
US10428150B2 (en) 2019-10-01
EP3991748A2 (en) 2022-05-04
EP3991748A3 (en) 2022-08-24
SG11201708220RA (en) 2017-11-29
RS62546B1 (sr) 2021-12-31
HRP20211980T1 (hr) 2022-04-01
US20240309097A2 (en) 2024-09-19
EA201792221A1 (ru) 2018-08-31
LT3280441T (lt) 2021-11-25
MX393951B (es) 2025-03-24
US20170210808A1 (en) 2017-07-27
WO2016164637A1 (en) 2016-10-13
JP2020202842A (ja) 2020-12-24
US20190062433A1 (en) 2019-02-28
EP3280441A4 (en) 2018-09-12
MX2017012802A (es) 2018-04-11
DK3280441T3 (da) 2021-11-15
SI3280441T1 (sl) 2022-01-31
SMT202200065T1 (it) 2022-03-21
NZ736674A (en) 2024-11-29
US20220185899A1 (en) 2022-06-16
PT3280441T (pt) 2021-11-30
ES2899227T3 (es) 2022-03-10
SG10201912087SA (en) 2020-02-27
US10308718B2 (en) 2019-06-04
JP7648584B2 (ja) 2025-03-18
HK1249445A1 (zh) 2018-11-02
US20220185898A1 (en) 2022-06-16
IL254887B1 (en) 2023-07-01
JP2025087841A (ja) 2025-06-10

Similar Documents

Publication Publication Date Title
JP7648584B2 (ja) 抗ソルチリン抗体及びその使用方法
JP7208157B2 (ja) 抗ソルチリン抗体及びその使用方法
JP2024009818A (ja) 抗Ｓｉｇｌｅｃ－７抗体及びその使用方法
TW201809004A (zh) 特異性針對過度磷酸化τ蛋白之抗體及其使用方法
JP2011523359A (ja) 抗ＰｉｒＢ抗体
JP2024529967A (ja) 抗ｓｉｒｐアルファ抗体及びその使用方法
HK1249445B (en) Anti-sortilin antibodies and methods of use thereof
EA043015B1 (ru) Антитела против сортилина и способы их применения

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1249445

Country of ref document: HK

CB03 Change of inventor or designer information
CB03 Change of inventor or designer information

Inventor after: A. Rosenthal

Inventor after: T - Schwabe

Inventor after: M Kneller RAS

Inventor after: R Pei ha

Inventor after: A. Cooper

Inventor before: A. Rosenthal

Inventor before: T - Schwabe

Inventor before: M Kneller RAS

GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment
TG01 Patent term adjustment